Silvia Novello Giorgio Scagliotti Peter Goodwin interviews Silvia Novello, and Giorgio Scagliotti from the University of Turin about harnessing insulin-like growth factor receptor inhibition in a phas
Silvia Novello
Giorgio Scagliotti
Peter Goodwin interviewsSilvia Novello, andGiorgio Scagliottifrom the University of Turin about harnessing insulin-like growth factor receptor inhibition in a phase II study which has shown clinical activity of figitumumab at least as significant as inhibitors of other growth factors already being used in cancer.